Molecular Modeling Studies on Benzimidazole Carboxamide Derivatives as PARP‐1 Inhibitors Using 3D‐QSAR and Docking
Authors:
Open Access
- 18 May 2011
- journal article
- research article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 78 (3) , 333-352
Abstract
Poly(ADP‐ribose) polymerases (PARPs) play significant roles in various cellular functions including DNA repair and control of RNA transcription. PARP‐1 inhibitors have been demonstrated to potentiate the effect of cytotoxic agents or radiation in a number of animal tumor models. To understand the structure–activity correlation of cyclic amine‐containing benzimidazole carboxamide‐based PARP‐1 inhibitors, we have carried out a combined molecular docking and three‐dimensional quantitative structure–activity relationship (3D‐QSAR) modeling study. Two types of satisfactory substructure‐based 3D‐QSAR models were built, including the comparative molecular field analysis (CoMFA) model (r2, 0.913; q2, 0.743) and comparative molecular similarity indices analysis (CoMSIA) model (r2, 0.869; q2, 0.734), to predict the biologic activity of new compounds. Docking studies were performed to explore the binding mode between all of the inhibitors and the PARP‐1 and produce the bioactive conformation of each compound in the whole data set. The docked conformer‐based alignment strategy gave the best 3D‐QSAR models, CoMFA model (r2, 0.899; q2, 0.712) and CoMSIA model (r2, 0.889; q2, 0.744), respectively. The structural insights obtained from both the 3D‐QSAR contour maps and molecular docking help to better interpret the structure–activity relationship. The information obtained from molecular modeling studies helped us to predict the activity of new inhibitors and further design some novel and potent PARP‐1 enzyme inhibitors.Keywords
This publication has 52 references indexed in Scilit:
- On Two Novel Parameters for Validation of Predictive QSAR ModelsMolecules, 2009
- Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituentBioorganic & Medicinal Chemistry Letters, 2008
- The role of poly(ADP-ribose) polymerase-1 in CNS diseaseNeuroscience, 2007
- Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymeraseBioorganic & Medicinal Chemistry Letters, 2005
- Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP‐ribose) polymerase‐1/2 inhibitorsFEBS Letters, 2005
- The PARP superfamilyBioEssays, 2004
- Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing FactorScience, 2002
- Validation of the general purpose tripos 5.2 force fieldJournal of Computational Chemistry, 1989
- The MIDAS display systemJournal of Molecular Graphics, 1988
- A new force field for molecular mechanical simulation of nucleic acids and proteinsJournal of the American Chemical Society, 1984